By Wendy Diller
Nearly two years ago, the FDA approved AstraZeneca PLC 's gefitinib (Iressa) and a year later ImClone Systems Inc....
Problems With Biomarkers: A Tale of Three Drugs
Enthusiasm for biomarkers to guide drug development and clinical decision making is high, but given how little we know about them, biomarkers are a risky investment, as shown by experiences with EGFR inhibitors.